ALOX5AP and asthma: Only the 5-LOX-inhibitor zileuton (Zyflo®) has been approved for pharmacotherapy of asthma (in the US), while FLAP antagonists are not yet on the market, despite intensive development (Gur et al., 2018a; Prescott et al., 2022).